ABSTRACT-M-5011
( Cyclooxygenase (COX) converts arachidonic acid (AA) to prostaglandin (PG) H2, which is further metabolized by other enzymes to various PGs and thromboxanes (1) . Formation of COX-derived products is dependent on the prior release of AA (2) , which is generated from phos pholipids by phospholipases (3) . COX exists in at least two distinct isoforms, COX-1 and COX-2 (4, 5) . The former, expressed constitutively in most cells and tissues (6, 7) , is assumed to be responsible for producing PGs involved in maintaining vital functions related to vascular homeo stasis, gastric mucosa and kidney (8) . COX-2, induced in many cells exposed to pro-inflammatory cytokines such as interleukin-1 (9, 10) , is found in synovia of patients with rheumatoid arthritis (RA) (11) and inflammatory tissues of experimental animal models (12, 13).
It is generally accepted that COX is an important target of nonsteroidal anti-inflammatory drugs (NSAIDs) (14). The anti-inflammatory properties of NSAIDs are achieved by the inhibition of COX-2, whereas the com mon side-effects of NSAIDs, such as gastrointestinal damage and renal dysfunctions, are associated with the inhibition of COX-1 (13, 15). Therefore, it is important to consider the efficacy/side-effect relationship of an NSAID by determining the pharmacological profile of different NSAIDs for COX isoforms.
It has been reported that significant differences exist in the subcellular locations of COX-1 and COX-2; the former functions predominantly in the endoplasmic reticulum, while the latter may be involved in events in both the endoplasmic reticulum and nuclear envelope (16). The differences in site-specific functions may mold the different sensitivities of COX-1 and COX-2 to NSAIDs (17). In addition, intracellular distribution of an NSAID is partly dependent on the pKa and lipid/water partition coefficient of the drug molecule (18). Therefore, enzyme preparations are not ideal for evaluating the pharmacological features of an NSAID for COX activ ities.
Since the synthesis of PGs is limited by the availabil ity of free AA (2), the regulation of AA release may be an important target for anti-inflammatory drugs in most tissues. Bradykinin (BK) is a potent pain-producing nonapeptide that is formed in damaged tissues (19). This peptide binds to receptors on the cell surface and triggers the activation of phospholipase A2 (20) .
It has been reported that a newly developed NSAID, d-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid (M 5011), elicits potent anti-inflammatory and analgesic
properties in animal models (21) . M-5011 is less potent than some other NSAIDs in inducing stomach and small intestine lesions in mice (21) . In this study, the effects of M-5011 on AA metabolism (PGE2 production and AA release) in human synovial fibroblasts were evaluated and compared with those of other NSAIDs.
MATERIALS AND METHODS

Drugs
propionic acid) was synthesized by Maruho Co., Ltd. (Osaka). In domethacin, ketoprofen and diclofenac sodium salt were the reference NSAIDs (Sigma Chemical, St. Louis, MO, USA). Stock solutions (100 mM) were prepared by dis solving these drugs in dimethylsulfoxide (Sigma Chemi cal) and stored at -20 C before use.
Synovial cells
Human rheumatoid synovium from the knee was ob tained from 2 patients (females, age: 46 and 64-year-old) undergoing synovectomy (Hayaishi Hospital, Osaka) with unknown medical history of RA. Adherent synovial fibroblasts, prepared by enzymatic digestion of the syno vium (22) , were cultured in Dulbecco's modified Eagle's medium (DMEM; ICN Biomedicals, Costa Mesa, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, ICN Biomedicals), 100 U/ml of peni cillin (Meiji Seika Co., Ltd., Tokyo) and 100 pg/ml of streptomycin (Meiji Seika) at 37V in a humidified 5 ° CO2 atmosphere. The cells were trypsinized and seeded at a density of 2 x 104 cells/cm2 in 24 and 48-well cell cul ture plates. Confluent cultures at passages 8 9 were used in all experiments.
Measurement of PGE2 production "Interleukin -1(3 (IL-1j3)-stimulated" cells were synovial cells incubated with human recombinant IL-1(3 (50 U/ml; Genzyme, Boston, MA, USA) in DMEM containing 10% FBS in 48-well culture plates at 37 C for 24 hr prior to washing 3 times with serum-free DMEM. Synovial cells incubated at 37V for 72 hr without changing the medium before rinsing with serum-free DMEM were designated as "non -stimulated" cells.
The effects of drugs on PGE2 production in synovial cells were evaluated in 2 experiments: i) the instantaneous inhibition of COX activity was determined by exposing IL-1~-stimulated and non-stimulated cells to 0.25 ml/well of DMEM containing 0.1 % bovine serum albumin (BSA; Intergen, New York, NY, USA) with AA (10 pg/ml; Serdary Research Laboratories, London, Canada) in the presence of a drug at the indicated concentrations at 37 C for 60 min; and ii) the reversibility of drug inhibition was investigated by incubating IL-1(3-stimulated cells with the respective drug (10-5 M) in DMEM containing 10% FBS at 37V for various intervals (up to 60 min) before wash ing 3 times with serum-free DMEM and exposing to 0.25 ml/well of DMEM containing 0.1% BSA with AA (10 pg/ml) at 371C for 60 min. On completion of the final incubation in all experiments, the medium was collected and stored at -20V before determination of PGE2 con tents by specific enzyme immunoassay (Cayman Chemi cal, Ann Arbor, MI, USA).
Determination of COX mRNA levels by the reverse transcriptase polymerase chain reaction (RT-PCR)
Non-stimulated synovial cells were incubated in DMEM containing 10% FBS with and without IL-1(3 (50 U/ml) at 37V for various intervals (up to 24 hr). The cells were rinsed with phosphate-buffered saline (PBS) and harvested for total RNA preparation by the guanidinium thiocyanate procedure. Reverse transcription was carried out by use of the first-strand cDNA synthesis kit (Phar macia Biotech, Uppsala, Sweden). According to the kit manual, total RNA (5 pg) dissolved in 20 p1 of RNase free water was incubated for 1 hr at 371C with 13 pl of first-strand cDNA reaction mixture containing Moloney murine leukemia virus reverse transcriptase, RNAguard, RNase/DNase-free BSA, dNTPs and 0.2 pg of random hexamers. The samples were then heated at 95V for 5 min to terminate the reverse transcription. The resulting cDNA was mixed with 10 mM Tris-HCI (pH 8.0) con taining 1 mM EDTA (final volume of 100 pl). Aliquots (1 pl) were used for PCR amplification with either COX or glyceraldehyde-3 phosphate dehydrogenase (GAPDH) specific primers. To assess if the amplification was achieved in an exponential range with a fixed number of cycles (23) , cDNA samples diluted in the same buffer to 1 : 2 and 1 : 8 were also amplified. A 1.1-kb cDNA coding for human GAPDH (50 pg; Clontech Laboratories, Palo Alto, CA, USA) was amplified and used as a standard reference. PCR was performed in a reaction buffer (50 p1) containing 10 mM Tris-HCI (pH 8.9), 1.5 mM MgC12, 80 mM KCI, 0.5 mg/ml BSA, 0.1 °7o sodium cholate, 0.1 % Triton X-100, 0. 
Western blot analysis
Non-stimulated synovial cells in 150-cm2 culture flasks were incubated in DMEM containing 10% FBS with and without IL-1~ (50 U/ml) at 371C for various intervals (up to 24 hr). On decantation of the medium, the cells were rinsed 3 times with ice-cold PBS and scraped into 1.5-ml samples of 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 10 mM EDTA, 1 mM diethyldithiocarbamate, 1 mM phenylmethylsulfonyl fluoride, 0.2 mM leupeptin, 50 pM pepstatin A and 1 % Triton X-100. COX polypeptides were solubilized by sonication of cell samples for 5 sec, and the sonicate was centrifuged at 15,000 x g for 30 min to remove insoluble contaminants. Protein contents in the supernatant were determined by DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA) using BSA as a standard. Solubilized proteins, precipitated by add ing 3 vol. of cold acetone (-20'C), were dissolved in 80 mM Tris-HCI (pH 8.0) containing 0.3 mM diethyl dithiocarbamate and 0.1 % Tween 20 to afford a 20 mg/ml solution. Dissolved proteins were then heated at 100V for 1 min with gel-loading buffer (50 mM Tris-HCl (pH 6.8) containing 10% glycerol, 2% SDS, 5% 2-mer captoethanol and 2 mg/ml bromophenol blue) in a ratio of 1 : 1 (v/v). Sample proteins (160 and 20g/lane for COX-1 and COX-2 analyses, respectively) were separated by SDS-polyacrylamide gel electrophoresis on 7.5% poly acrylamide gel and transferred electrophoretically (2 mA/cm, 1 hr) to polyvinylidene fluoride membranes (Im mobilon-P; Millipore, Bedford, MA, USA) with a trans fer buffer containing 25 mM Tris and 192 mM glycine. After blocking the membranes with 20 mM Tris-HC1 (pH 7.4) containing 150 mM NaC1(TBS) and 10% non-fat dry milk, the membrane was incubated overnight at 41C with Du Pont, Wilmington, DE, USA) in DMEM containing 10% FBS for 24 hr at 37V to label membrane phospholipids with radioactive AA (24) . After washing 3 times with serum-free DMEM, the labeled cells were exposed to 0.5 ml/well of DMEM containing 10% FBS with BK (20 jiM; Bachem, Torrance, CA, USA) at 37V for 3 hr in the presence of a drug at the indicated concentrations. At the end of incubation, the medium was collected and centrifuged at 2000 x g for 15 min at room temperature to remove any cells. The supernatant was isolated and its radioactivity was measured by a liq uid scintillation counter. The free [14C]AA content in the medium was analyzed by thin layer chromatography as previously described (24) .
Incorporation of AA in synovial cells
Synovial cells in 24-well cell culture plates were incu bated with [14C]AA (0.6 kBq/0.5 ml/well) in DMEM containing 10% FBS with or without M-5011 (10-6 M) at 37V for various intervals. At the end of incubation, the residual radioactivity in the medium was measured.
Statistical analyses
IC50 values were calculated by the least squares method. Statistical significance of data was evaluated by the un paired Student's t-test.
RESULTS
Expression and activities of COX-1 and COX-2 in cells
When the COX mRNA levels in non-stimulated cells were assessed with the RT-PCR method, which is more sensitive than the Northern blot procedure, COX-1 mRNA but not COX-2 mRNA was observed (Fig. la) . Dilution of cDNA samples followed by amplification demonstrated that PCR was performed in a semiquanti tative manner. Incubation of non-stimulated cells with IL-1(3 resulted in marked induction of COX-2 mRNA, which was detectable at 1 hr and attained a high content at 6 hr post-incubation.
The COX-2 mRNA expression persisted for at least 24 hr (Fig. 1b) . In contrast, the COX-1 mRNA contents were slightly affected by IL-1~. Furthermore, 2-hr incubation with 10%10 FBS, but not 0.1% BSA (data not shown), induced slight COX-2 mRNA expression. Western blotting manifested induction of COX-2 polypeptide at a position of 70 kDa in response to IL-1(3. The COX-2 accumulation, detectable at 1 hr, displayed the maximum content at 6 hr post-incubation, and it remained elevated thereafter for up to 24 hr (Fig. 2) . COX-2 polypeptide was undetectable in non-stimulated cells. Parallel expression kinetics of COX-2 mRNA and protein induced with IL-1p were observed. A weak COX 1 polypeptide band (70 kDa), unaffected by IL-1~ for 24 hr, was observed in non-stimulated cells at a position similar to that of authentic COX-1 (Fig. 2) . Fig. 1 . RT-PCR analyses of COX-1 and -2 mRNA expression in synovial cells. Non-stimulated cells were incubated with (+) and without (-) interleukin I j (IL-1(3, 50 U/ml) at 371C for the indi cated periods. Total RNA isolated from non-stimulated (a) and IL 1p-stimulated (b) cells was used in the RT-PCR assay for COX tran script. GAPDH mRNA was used to assess the integrity and sample equivalence. A sample of 50 pg of authentic GAPDH cDNA (Std) was amplified by PCR as the standard. PCR products were electro phoresed in an agarose gel, visualized by adding ethidium bromide and photographed under u.v. lighting. A 100-base-pair (bp) ladder was used as the molecular wt. marker. COX activities of IL-1j3 and non-stimulated cells were measured with 10 ,pg/ml AA as the substrate in DMEM containing 0.1% BSA. The kinetics of PGE2 production in cells were examined for 6 hr (Fig. 3) . PGE2 production in IL-1(3-stimulated cells exceeded that in non-stimulated cells by 10.1-fold at 60-min incubation.
Instantaneous inhibition of COX activities
The instantaneous effect of a drug on COX activities in synovial cells was evaluated by adding the drug and AA (10 pg/ml) simultaneously to the cells. All tested NSAIDs inhibited COX activities in IL-1,3-stimulated cells dose dependently (Fig. 4) . The IC50 values of M-5011 and ketoprofen were 4.4 x 10-' and 5.9 x 10-' M, respectively, whereas those of diclofenac (2.0 X 10-6 M) and indo methacin (> 5.0 x 10-6 M) were one order higher. Within the range of 10-8-5 x 10-6 M, although M-5011 was less potent than ketoprofen, the inhibition plateaus elicited by M-5011 and ketoprofen (propionic acid derivatives) were approximately 30-40% of the COX activities in non stimulated cells (Table 1) .
Time-dependent inhibition of COX-2
The mode of M-5011 action on COX-2 was examined with IL-113-stimulated cells. Cells incubated with a drug were subjected to increasing time intervals, washed and exposed to AA per se. Indomethacin and diclofenac revealed irreversible inhibitions on the COX-2 activity, which was dependent on the time of incubation with these inhibitors (Fig. 5) . Especially with respect to diclofenac, a rapid decay in COX-2 activity was observed. However, M-5011 and ketoprofen, which did not induce time dependent inhibition of COX-2 activities, behaved as re versible inhibitors.
Inhibition of [14C]AA release
Prelabeled synovial cells were incubated for 3 hr with or without BK (20 pM) in the presence of either M-5011
or ketoprofen (10-6 M). The amount of radiolabel released after the incubation in BK-stimulated cells was twofold that of the unstimulated cells (Table 2) . When free [14C]AA contents against the total releases in media incubated with BK, BK plus M-5011, BK plus ketoprofen or with the medium alone were expressed as a percentage, the values were 85.0%, 81.8%, 84.6% or 82.5 %, respectively. Therefore, the counts in the medium were mainly attributed to free (Table 3) . 
DISCUSSION
Although mRNA and polypeptide of COX-2 were not observed, both these cell components of COX-1 were lo cated in the non-stimulated synovial cells (Figs. 1a and 2) . Incubation of non-stimulated cells with IL-lp resulted in a parallel induction of COX-2 mRNA and COX-2 poly peptide 1 hr after initiation, and the expression persisted for at least 24 hr (Figs. lb and 2 ). In contrast, COX-1 ex pression only showed a minor variation under the same condition. These results suggest that PGE2 production by IL-1(3-stimulated and non-stimulated cells from exog enous AA is mainly attributed to the actions of COX-2 and COX-1, respectively.
M-5011 and ketoprofen were more potent instanta neous inhibitors of COX-2 activities in IL-1(3-stimulated cells than diclofenac and indomethacin (Fig. 4) . Both M 5011 and ketoprofen were reversible inhibitors of COX-2 (Fig. 5) . In contrast, indomethacin and diclofenac, which elicited time-dependent irreversible inhibition, manifest ed respective peak suppressions at 10 and 2 min post incubation. This is in agreement with a report that indo methacin exhibits time-dependent inhibition of COX-2 activities in vitro (25) . It has been reported that COX-2 activity is responsible for PGE2 production in the fluid exudate in rat subcutaneous air-pouch inflammation in duced by carrageenan (26) . In this model of inflamma tion, we have confirmed that orally administered M-5011 revealed an effective inhibitory activity (ID50) on PGE2 production in the pouch exudate at 0.28 mg/kg, a dose that exhibited a potency higher than indomethacin (1.00 mg/kg), diclofenac (0.48 mg/kg) and ketoprofen (0.87 mg/kg) (H. Kido et al., unpublished data). Although the mode of action of M-5011 and ketoprofen on COX-2 in vitro was partly different from that of indomethacin and diclofenac, these drugs may have similar in vivo anti inflammatory effects.
PGE2 production in IL-1-stimulated cells elevated markedly for the first 60 min followed by gradual in creases up to 6 hr after AA addition (Fig. 3) respectively. Since the NSAID-associated ulcerogenicity is attributed to inhibi tion of COX-1 (8), the effect of M-5011 on COX-1 activ ities in non-stimulated cells was compared with that of ketoprofen.
Both M-5011 and ketoprofen failed to manifest apparent dose-dependent inhibitions on COX-1 activities at all concentrations used (Table 1) . Although M-5011 was less potent than ketoprofen on COX-1 activ ities, the low ulcerogenicity of M-5011 could not be sufficiently explained by its lower inhibitory activity on COX-1. Formation of COX-derived products is depend ent on the prior release of AA from membrane phos pholipids (2, 3) . Therefore, the effect of M-5011 on AA release from synovial fibroblasts stimulated with BK, an important inflammatory mediator (19), was further com pared with that of ketoprofen. M-5011 inhibited [14C]AA release from synovial cells incubated with BK in a dose dependent manner, whereas ketoprofen hardly affected the response (Table 2) . It has been reported that intracel lular AA levels are regulated by the equilibrium between AA release from and uptake in phospholipids (27) . Thus, two possible mechanisms underlying the decrease in AA in the medium by M-5011 are conceivable. Firstly, M 5011 may actually inhibit AA release from synovial cells. Secondly, the agent may enhance AA uptake into syno vial cells. To evaluate these possibilities, the effects of M 5011 on [14C]AA uptake in synovial cells were examined in this study. It was found that M-5011 at 10-6 M did not enhance the [14C]AA uptake into the cells and revealed, in fact, a slight suppressive effect (Table 3 ). This result sug gests that the decreased rate of [14C]AA release by M-5011 is more likely due to the inhibition of [14C]AA release. Preliminary studies performed with human osteoarthritic synovial cells showed that M-5011 but not ketoprofen at 1010-10-5 M was also effective in inhibiting [14C]AA release from prelabeled cells stimulated with BK (data not shown). These results may explain, in part, the lower ulcerogenicity of M-5011 compared with ketoprofen in an animal model (21) .
While a plausible mechanism for the inhibition of
[14C]AA release by M-5011 is not known at present, decreased AA levels by M-5011 in the extracellular space may result in diminished production of PGs, since AA is taken up by neighboring cells before being catabolized to PGs (28) . In this study, effects of M-5011 on COX-1 and COX-2 activities were evaluated with the use of exog enous AA as the substrate. Further investigations to evaluate the effect of M-5011 on PGE2 production from endogenous AA at a cellular level are warranted. In summary, the present study demonstrated that M 5011 elicited an instantaneously potent inhibition against COX-2 and manifested a reversible inhibition on COX-2 activity in intact synovial cells. In addition, the cellular COX-1 activity was inhibited by M-5011, although to a lower extent (Table 1) . Furthermore, M-5011 inhibited
[14C]AA release from prelabeled synovial cells. It is likely that the effects of M-5011 on AA metabolism are, in part, responsible for its in vivo efficacy and safety profile.
